« Back

ICON reports 37% increase in revenues and 41% increase in EPS.

July 26, 2007

Backlog exceeds $1 billion for the first time (NASDAQ:ICLR)

Highlights – Second Quarter 2007

  • Second quarter net revenues increased 37% over the prior year, to $147.0 million.

  • Income from operations increased by 42%, to $16.1 million.

  • Diluted earnings per share increased by 41%, to 45 cents.

  • Record $230 million of net new business wins in the quarter, representing a book-to-bill ratio of 1.6.

Dublin, Ireland, July 26, 2007 – ICON (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2007.

Net revenues for the quarter were $147.0 million, representing a 36.9% increase over net revenues of $107.4 million for the same quarter last year.  Income from operations, after taking non-cash stock compensation charge of $1.4 million, calculated in accordance with SFAS 123®, was $16.1 million or 10.9% of revenue, compared to $11.3 million or 10.6% for the same quarter last year. Net income was $13.3 million or 45 cents per share on a diluted basis, compared with $9.3 million or 32 cents per share last year.

Year-to-date, net revenues were $283.1 million, representing a 37.5% increase over the same period last year.  Income from operations, after taking non-cash stock compensation charge of $2.6 million calculated in accordance with SFAS 123®, was $30.8 million or 10.9% of revenue, compared to $21.4 million or 10.4% last year. Net income was $25.6 million or 86 cents per share, compared with $16.8 million or 59 cents last year.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 53 days at June 30, 2007, a decrease from 59 days at March 31, 2007 and unchanged from 53 days at December 31, 2006.

For the quarter ended June 30, 2007, cash provided by operating activities was $22.2 million and capital expenditure was $17.9 million. For the six months, cash flow from operating activities was $19.4 million and capital expenditure was $30.4 million. As a result, the company's cash and short-term investments, net of debt, amounted to $91.1 million at June 30, 2007, compared to $97.9 million at December 31, 2006. 

“We are delighted with the second quarter's performance”, commented Chairman Dr. John Climax. “Revenue growth was very strong at 37%, and we made further progress in expanding margins which led to net income growth of 43% and EPS growth of 41%. Excellent net bookings of $230 million brought our backlog to over $1 billion, another milestone in ICON's progress, giving us strong confidence in the outlook for the remainder of the year”

“We recently completed the acquisition of DOCS International, a leading European based clinical research staffing organisation, which will be integrated with ICON's existing US based staffing business. The combined operation will give our clients greater flexibility when they run clinical projects internally, and give them access to a global pool of talent through one vendor”

The company will hold its second quarter conference call today, July 26, 2007 at 10:00 EST [15:00 Ireland & UK].  This call and linked slide presentation can be accessed live from our website at strRawhttp://www.iconclinical.comstrRaw.  A recording will also be available on the website for 90 days following the call.  In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”.  This calendar will be updated regularly.

The statements made in this Press Release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

The financial information presented herein has been prepared in accordance with U.S. GAAP.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has approximately 5,150 employees, operating from 63 locations in 33 countries. Further information is available at www.iconclinical.com.

Source: ICON plc

Contact : Investor Relations 1-888-381-7923 or

Ciaran Murray CFO + 353 –1-291-2000

Both at ICON.

ICON plc

Consolidated Income Statements (Unaudited)

Three and Six Months ended June 30, 2007 and June 30, 2006

(Dollars, in thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

June 30,

June 30,

2007

2006

2007

2006

Gross Revenue

207,383

153,744

394,123

294,388

Subcontractor costs

60,336

46,308

110,987

88,457

Net Revenue

147,047

107,436

283,136

205,931

Costs and expenses

Direct costs

83,875

60,014

162,432

114,718

Selling, general and administrative

42,662

32,397

81,346

62,677

Depreciation and amortization

4,450

3,689

8,606

7,134

Total costs and expenses

130,987

96,100

252,384

184,529

Income from operations

16,060

11,336

30,752

21,402

Interest income (net)

1,019

938

2,063

1,585

Income before provision of income taxes

17,079

12,274

32,815

22,987

Provision for income taxes

3,758

2,943

7,186

6,073

Minority interest

6

34

48

76

Net income

13,315

9,297

25,581

16,838

Net income per ordinary share

Basic

$0.46

$0.33

$0.89

$0.60

Diluted

$0.45

$0.32

$0.86

$0.59

Weighted average number of ordinary shares

Basic

28,684,201

28,265,490

28,624,350

28,174,762

Diluted

29,685,489

28,695,530

29,597,671

28,499,356

ICON plc

Summary Balance Sheet Data

June 30, 2007 and December 31, 2006

(Dollars, in thousands)

June 30,

December 31,

2007

2006

(Unaudited)

(Audited)

Cash and short-term investments

107,042

102,861

Short-term debt

(15,947)

(5,000)

Net cash

91,095

97,861

Accounts receivable

105,983

108,216

Unbilled revenue

104,740

89,977

Payments on account

(87,619)

(90,394)

Total

123,104

107,799

Working Capital

169,744

160,321

Total Assets

521,929

476,341

Shareholder's Equity

337,479

302,738

Source:

ICON plc

Contact:

Investor Relations 1-888-381-7923 or

Ciaran Murray CFO + 353 1 291 2000

both at ICON.

www.iconclinical.com

 

Back to press releases


Search Investor